Leerink Swann restated their outperform rating on shares of Kura Oncology Inc. (NASDAQ:KURA) in a research note published on Thursday morning. They currently have a $15.00 price objective on the stock.
A number of other equities analysts have also recently commented on KURA. Oppenheimer Holdings Inc. reissued an outperform rating and set a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research raised Kura Oncology from a hold rating to a buy rating and set a $3.75 target price for the company in a report on Wednesday, July 13th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Kura Oncology currently has an average rating of Buy and an average price target of $14.15.
Shares of Kura Oncology (NASDAQ:KURA) opened at 5.25 on Thursday. The firm has a 50-day moving average price of $6.16 and a 200-day moving average price of $4.22. Kura Oncology has a 1-year low of $2.50 and a 1-year high of $25.00. The company’s market cap is $98.40 million.
Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, August 10th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, equities analysts expect that Kura Oncology will post ($1.58) EPS for the current year.
A hedge fund recently bought a new stake in Kura Oncology stock. Alethea Capital Management LLC purchased a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned about 0.34% of Kura Oncology as of its most recent SEC filing. Institutional investors own 43.63% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.